SymBio Pharmaceuticals Ltd. (4582) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

RaQualia Pharma, Inc.

Fuji Pharma Co., Ltd.

Daito Pharmaceutical Co., Ltd.

Koa Shoji Holdings Co., Ltd.

Taiko Pharmaceutical Co., Ltd.

Healios KK

Fuso Pharmaceutical Industries Ltd.

Noile-Immune Biotech, Inc.

SymBio Pharmaceuticals Ltd.

SanBio Co., Ltd.

CanBas Co., Ltd.

Why is SymBio Pharmaceuticals Ltd. ?

The company has declared Negative results for the last 10 consecutive quarters

INTEREST(9M) At JPY 92.25 MM has Grown at inf%
NET SALES(Q) At JPY 336.84 MM has Fallen at -11.67%
ROCE(HY) Lowest at -174.65%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -34.86%, its profits have fallen by -92%

Underperformed the market in the last 1 year

Even though the market (Japan Nikkei 225) has generated returns of 36.73% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -34.86% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is SymBio Pharmaceuticals Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

SymBio Pharmaceuticals Ltd.

-34.86%

-0.24

124.94%

Japan Nikkei 225

36.73%

1.30

28.24%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.58%

EBIT Growth (5y)

1.88%

EBIT to Interest (avg)

-451.43

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.86

Sales to Capital Employed (avg)

0.65

Tax Ratio

0.86%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

24.63%

ROE (avg)

9.20%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.38

EV to EBIT

-1.22

EV to EBITDA

-1.22

EV to Capital Employed

10.70

EV to Sales

2.44

PEG Ratio

Dividend Yield

ROCE (Latest)

-877.08%

ROE (Latest)

-126.18%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

Higher at JPY -2,330.19 MM

-21What is not working for the Company

INTEREST(9M)

At JPY 92.25 MM has Grown at inf%

NET SALES(Q)

At JPY 336.84 MM has Fallen at -11.67%

ROCE(HY)

Lowest at -174.65%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.37 times

CASH AND EQV(HY)

Lowest at JPY 6,347.25 MM

DEBT-EQUITY RATIO (HY)

Highest at -70.83 %

Here's what is working for SymBio Pharmaceuticals Ltd.

Net Profit

Higher at JPY -2,330.19 MM

than preceding 12 month period ended Dec 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Here's what is not working for SymBio Pharmaceuticals Ltd.

Interest

At JPY 92.25 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Sales

At JPY 336.84 MM has Fallen at -11.67%

over average net sales of the previous four periods of JPY 381.34 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (JPY MM)

Inventory Turnover Ratio

Lowest at 1.37 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Cash and Eqv

Lowest at JPY 6,347.25 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -70.83 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio